This article examines five go-to-market gaps that can stop MedTech products and medical devices gaining customer adoption after regulatory approval in Asia-Pacific.
Regulatory approval feels like a finish line.
For many MedTech founders, it marks the moment years of engineering, clinical work and investment finally become something tangible. The product is approved. The technology works. The evidence is strong.
Then sales begin to slow.
Clinicians express interest but orders do not materialise. Distributors say the product looks promising but momentum stalls. Procurement teams ask questions the sales deck never anticipated. Months after launch, founders begin asking a difficult question.
“Why aren't we seeing the customer traction we expected?”
This is a recurring go-to-market challenge for founders with a registered product in the MedTech and medical devices sector in Asia-Pacific.
For teams working in MedTech and medical devices, approval is only one milestone. Sales also depend on customer insight, positioning and go-to-market readiness.
Regulatory approval allows a product to enter a market; it does not establish customer demand or complete the hospital buying process.
Registration may allow a product to be offered in a market. Customer need, buying behaviour, positioning and distributor execution determine whether interest can progress towards orders.
For a registered product in the MedTech and medical devices sector, the next questions are practical: which customers have a relevant need, how do they make purchasing decisions, what alternatives do they use, and can the distributor support the route from evaluation to order?
Gap 1: MedTech founders know their product better than customers know their problem
Founders naturally become experts in their technology.
Customers are experts in their own clinical and operational environment.
A clinician may value workflow improvement more than another technical feature.
A procurement manager may care about service reliability, training requirements and total cost of ownership.
A hospital executive may be thinking about patient throughput, budget impact and operational efficiency rather than device specifications.
Every stakeholder is solving a different problem.
That means one value proposition rarely works for everyone.
What problem does each stakeholder believe we solve — in their own words?
Structured customer conversations are not about collecting opinions. They are about understanding the language, priorities and objections that shape real buying decisions across the healthcare ecosystem.
Gap 2: Interest is not adoption.
Many MedTech founders mistake positive conversations for customer traction.
- “Interesting product.”
- “We'd like to trial it.”
- “Come back after budget planning.”
These are encouraging conversations — but they are not adoption signals.
Sales traction begins when customers move from curiosity to commitment through:
- clinical evaluation,
- procurement engagement,
- distributor commitment,
- tender inclusion,
- repeat purchasing.
Where exactly is the customer journey stopping?
Understanding where momentum disappears often reveals whether the challenge is clinical education, positioning, pricing, workflow integration or go-to-market execution.
Gap 3: Asia-Pacific is not one MedTech market.
Many founders describe "Asia" as a target market.
In reality, Asia-Pacific is a collection of very different healthcare systems, purchasing processes and customer environments.
- reimbursement pathways
- procurement models
- distributor capability
- public versus private healthcare
- competitive pricing
- clinician influence
- tender processes
A go-to-market approach that works in one APAC country may not work in another. Validate the buying pathway, customer priorities and channel requirements in each target market.
Which market gives us the highest probability of meaningful early traction?
Gap 4: Your value proposition changes depending on who is listening.
Technical differentiation does not automatically become customer-relevant value.
Customers respond to outcomes, not specifications.
- Faster diagnosis.
- Easier workflow.
- Reduced training burden.
- Operational efficiency.
- Better patient pathways.
Product positioning translates technical capability into practical value for multiple decision-makers.
Can every stakeholder explain why this product matters without reading our brochure?
Gap 5: Measuring activity instead of customer orders
Hospital visits, demonstrations and distributor updates can create the impression of progress without showing whether customers are moving towards a purchase.
For registered MedTech and medical devices, track the steps that connect account activity to a buying decision:
- qualified target accounts and confirmed customer needs,
- clinical evaluations with an agreed decision process,
- procurement engagement and budget confirmation,
- quotes, tender progress and purchase orders,
- distributor sell-through, utilisation and repeat orders where relevant.
Which activities are producing measurable progress towards customer orders?
A practical go-to-market readiness checklist
Before investing further in a launch or adding channel resources, test the assumptions behind the plan:
- Customer: Have we validated a specific problem with the people who experience it and the people who influence purchasing?
- Market: Have we prioritised a country, clinical segment and account type rather than treating Asia-Pacific as one market?
- Competition: Can we explain why a buyer would change from the existing solution or supplier?
- Buying behaviour: Do we understand budget ownership, the information procurement requires and timing?
- Channel capability: Can the distributor reach target accounts, progress opportunities and support customers after the sale?
- Proof: What specific customer or sales proof would justify the next investment, and what result would make us change direction?
Use the Free MedTech Prospecting Training with ICP Scorecard in KawaHive Lab to structure early account research. The tools support disciplined prospecting; they do not replace customer validation or local regulatory advice.
Regulatory approval is the beginning, not the end.
A MedTech product can be clinically excellent and from a go-to-market perspective unclear at the same time.
That uncertainty often appears as slower sales, hesitant distributors, inconsistent messaging or disappointing market traction after launch.
Rather than assuming the market "doesn't get it", identify where the go-to-market gap exists.
Sometimes it is positioning.
Sometimes it is customer understanding.
Sometimes it is target-market prioritisation.
Sometimes it is go-to-market execution.
The goal is not more activity. The goal is making better go-to-market decisions, earlier.
A question worth asking before your next GTM decision
Before investing in another sales campaign, distributor search or market launch, ask yourself one question.
“What proof do we have that we’re solving the right go-to-market problem?”
The answer often changes the next decision more than another sales presentation does.
That is where a clearer go-to-market decision begins.